UroGen Pharma Ltd. (URGN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about UroGen Pharma Ltd. (URGN)
Company Performance

Current Price

as of Oct 16, 2024

$12.60

P/E Ratio

N/A

Market Cap

$530.64M

Description

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Metrics

Overview

  • HQPrinceton, NJ
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerURGN
  • Price$12.6+2.77%

Trading Information

  • Market Cap$530.64M
  • Float90.70%
  • Average Daily Volume (1m)775,979
  • Average Daily Volume (3m)570,495
  • EPS-$3.27

Company

  • Revenue$85.01M
  • Rev Growth (1yr)3.35%
  • Net Income-$33.40M
  • Gross Margin89.80%
  • EBITDA Margin-117.06%
  • EBITDA-$25.58M
  • EV$475.00M
  • EV/Revenue5.59
  • P/EN/A
  • P/S5.46
  • P/B17.11